Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Codiak BioSciences, Inc. CDAK
$0.06
На 18:03, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
2828773.00000000
-
week52high
4.25
-
week52low
0.02
-
Revenue
22935000
-
P/E TTM
0
-
Beta
3.93495100
-
EPS
-0.46000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 авг 2023 г. в 10:59
Описание компании
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Goldman Sachs | Neutral | Buy | 01 сент 2022 г. |
| Goldman Sachs | Buy | Buy | 05 июл 2022 г. |
| Goldman Sachs | Buy | Buy | 24 мая 2022 г. |
| Wedbush | Outperform | Outperform | 22 февр 2022 г. |
| Goldman Sachs | Buy | 11 февр 2022 г. | |
| Goldman Sachs | Neutral | Neutral | 07 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Barna Nicole | A | 105000 | 105000 | 24 янв 2023 г. |
| WILLIAMS DOUGLAS E | A | 465000 | 465000 | 24 янв 2023 г. |
| Howze Yalonda | A | 150000 | 150000 | 24 янв 2023 г. |
| Bain Linda | A | 185000 | 185000 | 24 янв 2023 г. |
| Konstantinov Konstantin | A | 145000 | 145000 | 24 янв 2023 г. |
| Sathyanarayanan Sriram | A | 140000 | 140000 | 24 янв 2023 г. |
| Mauro David J | A | 190000 | 190000 | 24 янв 2023 г. |
| Bain Linda | D | 3120 | 1880 | 20 янв 2023 г. |
| Barna Nicole | D | 8112 | 836 | 20 янв 2023 г. |
| Howze Yalonda | D | 2488 | 1512 | 20 янв 2023 г. |
Новостная лента
Codiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Lags Revenue Estimates
Zacks Investment Research
03 ноя 2022 г. в 18:48
Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 6.10% and 70.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity of Two Engineered Exosome Intravenous Candidates Targeting Macrophages
GlobeNewsWire
05 окт 2022 г. в 08:00
– Data to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting –
Codiak BioSciences, Inc. (CDAK) Reports Q2 Loss, Tops Revenue Estimates
Zacks Investment Research
04 авг 2022 г. в 18:48
Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 61.54% and 701.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Codiak BioSciences' Engineered Exosome Candidates Show Early Antitumor Activity
Benzinga
30 июн 2022 г. в 09:52
Codiak BioSciences Inc (NASDAQ: CDAK) announced platform-validating clinical data from Phase 1 trials of exoSTING and exoIL-12, and it plans to advance both candidates into Phase 2 trials. In an open-label Phase 1 trial, exoIL-12 demonstrated a differentiating favorable safety.
Codiak BioSciences, Inc. (CDAK) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
05 мая 2022 г. в 19:34
Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 55% and 0.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?